Ophthalmic Drugs Market .pdf
Original filename: Ophthalmic Drugs Market.pdf
This PDF 1.4 document has been generated by Online2PDF.com, and has been sent on pdf-archive.com on 20/04/2018 at 10:14, from IP address 1.23.x.x.
The current document download page has been viewed 242 times.
File size: 186 KB (7 pages).
Privacy: public file
Download original PDF file
Ophthalmic Drugs Market
Global Industry Analysis, Trends, Market Size and Forecasts up to 2023
A latest report has been added to the wide database of Ophthalmic Drugs Market by Infinium Global Research. This report studies the
Ophthalmic Drugs Market by disease condition (allergy, glaucoma, dry eye disorder and retinal disorder), dispenses type (prescription
and over the counter) market status and outlook of global and major regions, from manufacturers, and end industries. The objective of
the study is to identify market sizes of different segments & countries in recent years and to forecast the values for the next six years.
Ophthalmic Drugs Market provides opportunities in micro markets for stakeholders to invest along with the detailed analysis of
competitive landscape, latest trends, and product offerings of the major companies in the Ophthalmic Drugs Market. According to
report the global ophthalmic drugs market is projected to grow at a CAGR of 5.4% over the forecast period of 2017-2023.
Ophthalmic drugs are the drugs designed for the treatment of eye diseases and disorders. This administration of drug can be done by
instillation of a cream, an ointment, or a liquid drop preparation in the conjunctiva SAC. The correct strength and amount of the drug
are selected, and the medication is instilled into the eye or eyes as directed. The main reason of continuingly strong interest of
scientists in these drugs forms is the problem of a low bioavailability of medicinal substance after the application to the eyeball. The
ability to increase the bioavailability of the active substances, reducing the susceptibility of drug forms to defense mechanisms of the
human eye, extending contact time of drug with the cornea, increasing the penetration through the complex anatomical structure of
the eye, and providing controlled release of drugs into the eye tissues which allows reducing the drug application frequency, witnesses
the importance of ophthalmic drugs among the aging population suffering from eye disorders are some of the factors contributing to
the growth in the global ophthalmic drugs market.
The key factors driving the growth of ophthalmic drugs market are considered to be increasing geriatric population with rising global
population, increase in prevalence of eye disorders, technological advancement, and increasing awareness in healthcare spending.
Moreover, challenges faced by ophthalmic drugs market include absence of health insurance in developing countries regarding eye
diseases and lack of awareness among the people regarding eye diseases and disorders in underdeveloped and developing countries.
One of the key opportunities for new entrants is securing drugs through a licensing agreement with major players such as novartis and
bayer, which could boost their growth over the forecast period.
The report on global ophthalmic drugs market covers segments such as, disease condition and dispenses type. On the basis of disease
condition the global ophthalmic drugs market is categorized into allergy, glaucoma, dry eye disorder and retinal disorder. On the basis
of dispense type the global ophthalmic drugs market is categorized into prescription and over the counter.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this
section the key trends and market size for each geography is provided over the period of 2015-2023.
The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan,
India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the
European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific
region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region
is projected to experience a growth at a CAGR of x.x% over the period of 2017-2023.
The report provides profiles of the companies in the global ophthalmic drugs market such as, Abbott Healthcare, Allergan Plc, Johnson
& Johnson, Bayer, Valeant Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co., Novartis AG, Renegeron and Santen Pharmaceuticals
Make an Enquiry
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report
provides insights on the factors that are driving and restraining the global ophthalmic drugs market. Moreover, IGR-Growth Matrix
analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report
provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of ophthalmic drugs
market. Moreover, the study highlights current market trends and provides forecast from 2017-2023. We also have highlighted future
trends in the ophthalmic drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis
given in each regional market brings an insight on the market share of the leading players. This report will help manufacturers,
suppliers and distributors of the ophthalmic drugs market to understand the present and future trends in this market and formulate
their strategies accordingly.
Get a Sample Request
Table of Contents:1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Global Ophthalmic Drugs Market Overview
3.2. Market Dynamics
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.5. Competitive Landscape in the Global Ophthalmic Drugs Market
4. Global Ophthalmic Drugs Market by Disease Condition
4.3. Dry Eye Disorder
4.4. Retinal Disorder
5. Global Ophthalmic Drugs Market by Dispense Type
5.2. Over the Counter
6. Global Ophthalmic Drugs Market by Region 2017-2023
6.1. North America
6.1.1. North America Ophthalmic Drugs Market by Disease Condition
6.1.2. North America Ophthalmic Drugs Market by Dispense Type
6.1.3. North America Ophthalmic Drugs Market by Country
6.2.1. Europe Ophthalmic Drugs Market by Disease Condition
6.2.2. Europe Ophthalmic Drugs Market by Dispense Type
6.2.3. Europe Ophthalmic Drugs Market by Country
6.3.1. Asia-Pacific Ophthalmic Drugs Market by Disease Condition
6.3.2. Asia-Pacific Ophthalmic Drugs Market by Dispense Type
6.3.3. Asia-Pacific Ophthalmic Drugs Market by Country
6.4.1. RoW Ophthalmic Drugs Market by Disease Condition
6.4.2. RoW Ophthalmic Drugs Market by Dispense Type
6.4.3. RoW Ophthalmic Drugs Market by Sub-region
7. Company Covered
7.1. Abbott Healthcare
7.2. Allergan Plc
7.3. Johnson & Johnson
7.5. Valeant Pharmaceuticals, Inc.
7.6. Pfizer, Inc.
7.7. Merck & Co.
7.8. Novartis AG
7.10. Santen Pharmaceuticals Company Ltd.
Click the Below Full Report Link